CyberKnife Market (2026 - 2033)

CyberKnife Market Summary

The CyberKnife market size was valued at USD 795.2 million in 2025 and is projected to grow from USD 922.8 million in 2026 to USD 2398.3 million by 2033, at a CAGR of 14.6% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.6% in 2025. The increasing prevalence of cancer, recent product launches, and growing preference for non-invasive or minimally invasive procedures over surgery are the factors propelling the growth of the industry.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The increasing prevalence of cancer is the most prominent factor driving the market growth. Factors contributing to the rise of the prevalence of cancer include increasing tobacco use, rising alcohol consumption, lack of physical activity, and growing adoption of unhealthy diets by individuals.

To learn more about this report, Download Free Sample Report

A 2024 CDC study highlights that nearly 90% of lung cancer fatalities are attributable to smoking or exposure to secondhand smoke. This underscores that tobacco consumption significantly elevates cancer risk. Consequently, a growing smoking population correlates with an increased number of individuals at risk of developing lung cancer, emphasizing the urgent need for targeted public health interventions.

New product launches by the key players are also substantially contributing to market growth. For instance, in August 2024, Apollo Cancer Centre Bengaluru launched South Asia’s first CyberKnife*S7 FIM Robotic Radio Surgery System in India. This next-generation platform offers non-invasive radiation therapy to effectively treat both cancerous and benign tumors throughout the body, enhancing the operational efficiency of clinicians.

Several factors, including reduced hospital stays, lower trauma, quicker recovery times, and cost-effectiveness compared to surgical procedures, encourage more patients to choose non-invasive or minimally invasive options. These procedures effectively target cancer cells, damaging their DNA and inhibiting spread. Consequently, ongoing technological advancements in cancer treatment are anticipated to drive market growth for these modalities.

Market Dynamics

The CyberKnife market is experiencing significant growth due to growing healthcare providers adoption of robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) systems to deliver highly precise, non-invasive radiation treatments for complex medical conditions. CyberKnife system is one that makes use of high-tech technology to ensure accurate delivery of radiation treatments in the form of highly localized treatments that minimize exposure of radiation on the surrounding healthy tissues through image guidance, real-time tumor tracking, and robotic radiation delivery. The treatment systems are commonly used in the management of tumors, cancers, vascular malformations, and other complex health complications. Some of the key factors propelling market growth include the increased global prevalence of cancer, higher need for non-invasive alternatives, advancements in precision oncology, and preference for outpatient treatment solutions. Advancements in motion tracking technologies, adaptive radiotherapy, AI-assisted treatment planning, and image-guided radiation delivery are some of the factors that are helping to improve treatment outcomes. Growing investment in advanced oncology infrastructure, increased awareness about stereotactic radiotherapy, and personalized cancer care approach are some of the other factors supporting the demand for CyberKnife systems.

Application Insights

Based on application, the cancer segment led the market with the largest revenue share of 41.5% in 2025, approximately 1,958,310 new cancer cases will be diagnosed in the U.S., with the five most prevalent types being breast, prostate, lung, bronchial, and colorectal cancers. Furthermore, the increasing adoption of CyberKnife technology for treating various cancer types is contributing to significant growth in this market segment. This trend highlights the growing recognition of innovative treatment options in enhancing patient outcomes and advancing cancer care.

Vascular malformation is expected to grow at the fastest CAGR of 17.8% over the forecast period, owing to their effectiveness in managing arteriovenous malformations. This non-surgical, non-invasive procedure utilizes a precisely targeted beam of radiation to damage the blood vessel walls, effectively closing the AVM. These treatments are performed with exceptional accuracy by leveraging cutting-edge technology, underscoring their potential to enhance patient outcomes.

End-use Insights

Based on end use, the hospitals segment led the market with the largest revenue share of 49.2% in 2025, fueled by highly skilled professionals and an increasing volume of patient visits. Moreover, the rise in the number of hospitals aimed at accommodating the growing patient demand further contributes to segment growth. These factors highlight the evolving healthcare landscape and the commitment to enhancing patient care through expanded resources and expertise.

To learn more about this report, Download Free Sample Report

Outpatient facilities are projected to grow at the fastest CAGR of 17.8% over the forecast period. Ambulatory surgical centers  and specialty clinics are anticipated to grow significantly during the forecast period. This growth is primarily attributed to advantages such as shorter waiting times and lower overall costs, including reduced out-of-pocket patient expenses. These factors enhance accessibility and affordability, positioning these facilities as increasingly attractive options for patients seeking efficient and cost-effective surgical care.

Regional Insights

North America dominated the cyberknife market with the largest revenue share of 41.6% in 2025. Factors such as the rising prevalence of chronic diseases, a significant shift towards painless and non-invasive surgical procedures, and increasing demand for efficient treatments are driving market growth in the region. According to the American Society for Radiation Oncology, the number of radiation facilities in the U.S. grew from 1,987 in 2005 to 2,332 in 2020, reflecting a 17.0% increase. Investments in healthcare infrastructure and favorable reimbursement policies further enhance patient access to innovative treatments.

To learn more about this report, Download Free Sample Report

U.S. CyberKnife Market Trends

The cyberknife market in the U.S. held the largest share in the North America region in 2025, fueled by the high incidence of cancer cases, with approximately 1.96 million new diagnoses in 2023. Technological advancements in CyberKnife systems and a shift towards outpatient treatment options drive demand for these innovative therapies, providing patients greater accessibility and satisfaction.

Europe CyberKnife Market Trends

Europe cyberknife market held a substantial market share in 2025, driven by the rising cancer burden, with approximately 3.7 million new cases reported annually. Advanced radiation therapies, rising healthcare expenditures, and a growing preference for minimally invasive procedures among patients and healthcare providers contribute to market growth.

The cyberknife market in Germany is expected to grow lucratively in the forecast period, aided by its aging population, with approximately 22% of citizens aged 65 and older. The high prevalence of chronic diseases, including cancer, alongside advanced healthcare infrastructure and investment in cutting-edge technologies, drives the adoption of CyberKnife systems for effective treatment options.

Latin America CyberKnife Market Trends

Latin America cyberknife market is expected to register the fastest CAGR of 19.1% in the forecast period. The region is experiencing an increasing incidence of cancer, with projections indicating over 1 million new cases annually. Enhanced government initiatives to improve healthcare access and affordability and growing awareness of advanced treatment options among patients contribute to the market’s growth.

The cyberknife market in Brazil dominated the Latin America cyberknife market in 2025, supported by a growing population of over 213 million people. The number of cancer cases is expected to rise to 600,000 annually by 2025. Investments in healthcare infrastructure and advancements in medical technology promote the adoption of innovative treatments such as CyberKnife for effective cancer management.

Key CyberKnife Company Insights

Some key companies operating in the market include Microsoft Corporation, IBM Corporation, Amazon.com, Inc., and Google LLC (Alphabet Inc.). In an attempt to establish a strong position in the market, key players are carrying out various strategic initiatives such as mergers and acquisitions, partnerships, collaboration, and expansion. These strategies help companies expand the reach of their products and enhance the overall quality of their products with additional expertise.

• Accuray is a leading entity in the CyberKnife market, offering the CyberKnife® S7 system for precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It leverages advanced technologies to improve patient outcomes and optimize clinical workflows.
• Koninklijke Philips contributes to the CyberKnife market by providing advanced imaging and diagnostic technologies that enhance radiation therapy. While not a primary manufacturer of CyberKnife systems, Philips’ solutions support precise tumor targeting during radiosurgery procedures.

Key CyberKnife Companies:

The following key companies have been profiled for this study on the cyberKnife market.

• Advanced Micro Devices

• AiCure

• Arm Limited

• Atomwise, Inc.

• Ayasdi AI LLC

• Baidu, Inc.

Recent Developments

• In January 2025, Accuray Incorporated announced the approval of the Radixact SynC and CyberKnife S7 Systems by China’s National Medical Products Administration, enhancing its radiation therapy portfolio in the region.

• In June 2024, Heidelberg University Hospital in Germany invested in the Radixact System, enhancing cancer patient care with advanced radiation therapy technology from Accuray Incorporated.

• In September 2023, Kenyatta University Teaching, Referral, and Research Hospital in Kenya commissioned the first CyberKnife radiotherapy system in Sub-Saharan Africa, advancing access to high-precision cancer treatment.

Global CyberKnife Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cyberknife market report based on application, end-use, and region:

To learn more about this report, Download Free Sample Report

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Tumor

  • Cancer

  • Vascular Malformation

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Outpatient Facilities

  • Research & Manufacturing

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The cyberKnife market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each cyberKnife segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations